Saltar al contenido
Merck

I4161

Sigma-Aldrich

IL-2 mouse

≥97% (SDS-PAGE), recombinant, expressed in E. coli, lyophilized powder, suitable for cell culture

Sinónimos:

mIL-2, IL-2, T-cell growth factor

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

MDL number:
UNSPSC Code:
12352202
NACRES:
NA.77

product name

Interleukin-2 from mouse, IL-2, recombinant, expressed in E. coli, carrier free

biological source

mouse

Quality Level

recombinant

expressed in E. coli

assay

≥97% (SDS-PAGE)

form

lyophilized powder

potency

≤0.2 ng/mL ED50

quality

endotoxin tested

mol wt

17.2 kDa

packaging

pkg of 5X20 μg
pkg of 20 μg

technique(s)

cell culture | mammalian: suitable

impurities

≤0.200ng/ml

color

white

UniProt accession no.

shipped in

dry ice

storage temp.

−20°C

Gene Information

mouse ... Il2(16183)

¿Está buscando productos similares? Visita Guía de comparación de productos

Biochem/physiol Actions

Interleukin-2 (IL-2) is a powerful immunoregulatory lymphokine produced by T-cells in response to antigenic or mitogenic stimulation. Recombinant human IL-2 is a 15.5 kDa protein, containing 134 amino acid residues including one intrachain disulfide bond.

Physical form

Lyophilized with no additives.

Reconstitution

Centrifuge vial prior to opening. Reconstitute the contents of the vial in water to a concentration range of 0.1-1.0 mg/mL.
IL-2 is a powerful immunoregulatory lymphokine produced by T-cells in response to antigenic or mitogenic stimulation. IL-2/IL-2R signaling is required for T-cell proliferation and other fundamental functions which are essential for the immune response. IL-2 stimulates growth and differentiation of B-cells, NK cells, lymphokine activated killer cells, monocytes, macrophages and oligodendrocytes. Recombinant human IL-2 is a 15.5 kDa protein, containing 134 amino acid residues including one intrachain disulfide bond.

pictograms

Exclamation mark

signalword

Warning

hcodes

Hazard Classifications

Eye Irrit. 2 - STOT SE 3

target_organs

Respiratory system

Storage Class

10 - Combustible liquids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Los clientes también vieron

Joaquin De Haro et al.
Journal of vascular surgery, 62(6), 1625-1631 (2014-07-22)
This study assessed the effect of cellular and humoral autoimmune response inhibition after immunization with β2-glycoprotein I (β2-GPI) and the effect of immunomodulation with interleukin (IL)-2 and IL-10 in the development of early atherosclerotic vascular lesion in a murine model.
Nabil Ahmed et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33(15), 1688-1696 (2015-03-25)
The outcome for patients with metastatic or recurrent sarcoma remains poor. Adoptive therapy with tumor-directed T cells is an attractive therapeutic option but has never been evaluated in sarcoma. We conducted a phase I/II clinical study in which patients with
Fang-Ting Lu et al.
Journal of autoimmunity, 61, 62-72 (2015-06-15)
Thymic CD4(+) FoxP3(+) regulatory T (Treg) cells are critical for the development of immunological tolerance and immune homeostasis and requires contributions of both thymic dendritic and epithelial cells. Although B cells have been reported to be present within the thymus
Sushama Telwatte et al.
Nucleic acids research, 43(6), 3256-3271 (2015-03-15)
Resistance to combined antiretroviral therapy (cART) in HIV-1-infected individuals is typically due to nonsynonymous mutations that change the protein sequence; however, the selection of synonymous or 'silent' mutations in the HIV-1 genome with cART has been reported. These silent K65K
Haiying Qin et al.
Blood, 126(5), 629-639 (2015-06-05)
Adoptive transfer of T cells genetically modified to express chimeric antigen receptors (CARs) targeting the CD19 B cell-associated protein have demonstrated potent activity against relapsed/refractory B-lineage acute lymphoblastic leukemia (B-ALL). Not all patients respond, and CD19-negative relapses have been observed.

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico